|
|
 Previous Article | Table of Contents | Next Article 
Interleukin-6 is a potent myeloma-cell growth factor in patients with
aggressive multiple myeloma
XG Zhang, B Klein and R Bataille
INSERM U291, Montpellier, France.
It has recently been demonstrated that interleukin-6 (IL-6) is a potent
myeloma-cell growth factor in the majority of patients with multiple
myeloma (MM). Using an anti-bromodeoxyuridine monoclonal antibody (MoAb) to
specifically count myeloma cells in the S-phase (ie, labeling index, LI),
we demonstrate that the IL-6 responsiveness of myeloma cells in vitro is
directly correlated with their LI in vivo. Myeloma cells from all 13
patients with high LIs in vivo (greater than or equal to 1%) responded in
vitro to IL-6, the strongest response occurring in cells from five patients
with plasma-cell leukemia. In contrast, the cells of only two of eight
patients with low myeloma-cell LIs in vivo (less than 1%) responded to IL-6
in vitro. After seven days of culturing with 1,000 U/mL recombinant IL-6
(rIL-6), the median LI value in the first group of patients (in vivo LI
greater than or equal to 1%) was 11%, ie 11 times higher (P less than .01)
than the median LI value (1%) in the second group of patients (in vivo LI
less than 1%). Thus, the in vitro IL-6 responsiveness of myeloma cells is
directly related to their in vivo proliferative status, and hence to the
severity of the disease.
Volume 74,
Issue 1,
pp. 11-13,
07/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. D. Pylypchuk, L. J. Schouten, R. A. Goldbohm, H. C. Schouten, and P. A. van den Brandt
Body Mass Index, Height, and Risk of Lymphatic Malignancies: A Prospective Cohort Study
Am. J. Epidemiol.,
August 1, 2009;
170(3):
297 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Birmann, E. Giovannucci, B. Rosner, K. C. Anderson, and G. A. Colditz
Body Mass Index, Physical Activity, and Risk of Multiple Myeloma
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2007;
16(7):
1474 - 1478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant
The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells
Clin. Cancer Res.,
June 15, 2005;
11(12):
4589 - 4600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Miceli, R. Atoui, R. Walker, T. Mahfouz, N. Mirza, J. Diaz, G. Tricot, B. Barlogie, and E. Anaissie
Diagnosis of Deep Septic Thrombophlebitis in Cancer Patients by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Scanning: A Preliminary Report
J. Clin. Oncol.,
May 15, 2004;
22(10):
1949 - 1956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-T. Brenne, T. Baade Ro, A. Waage, A. Sundan, M. Borset, and H. Hjorth-Hansen
Interleukin-21 is a growth and survival factor for human myeloma cells
Blood,
May 15, 2002;
99(10):
3756 - 3762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Berenson, J. J. Crowley, T. M. Grogan, J. Zangmeister, A. D. Briggs, G. M. Mills, B. Barlogie, and S. E. Salmon
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
Blood,
May 1, 2002;
99(9):
3163 - 3168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Angelo, M. Talpaz, and R. Kurzrock
Autocrine Interleukin-6 Production in Renal Cell Carcinoma: Evidence for the Involvement of p53
Cancer Res.,
February 1, 2002;
62(3):
932 - 940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Nicholas
Evolutionary aspects of oncogenic herpesviruses
Mol. Pathol.,
October 1, 2000;
53(5):
222 - 237.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. E. Barton, J. Cullison, J. Jackson, and T. Murphy
A Model that Reproduces Syndromes Associated with Human Multiple Myeloma in Nonirradiated SCID Mice
Experimental Biology and Medicine,
February 1, 2000;
223(2):
190 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
Blood,
January 15, 2000;
95(2):
610 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wan, H. Wang, and J. Nicholas
Human Herpesvirus 8 Interleukin-6 (vIL-6) Signals through gp130 but Has Structural and Receptor-Binding Properties Distinct from Those of Human IL-6
J. Virol.,
October 1, 1999;
73(10):
8268 - 8278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sawamura, X. Meng, S. Ina, M. Sato, K. Tamai, K. Hanada, and I. Hashimoto
Induction of Keratinocyte Proliferation and Lymphocytic Infiltration by In Vivo Introduction of the IL-6 Gene into Keratinocytes and Possibility of Keratinocyte Gene Therapy for Inflammatory Skin Diseases Using IL-6 Mutant Genes
J. Immunol.,
November 15, 1998;
161(10):
5633 - 5639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4727 - 4737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nicholas, J.-C. Zong, D. J. Alcendor, D. M. Ciufo, L. J. Poole, R. T. Sarisky, C.-J. Chiou, X. Zhang, X. Wan, H.-G. Guo, et al.
Novel Organizational Features, Captured Cellular Genes, and Strain Variability Within the Genome of KSHV/HHV8
J Natl Cancer Inst Monographs,
April 1, 1998;
1998(23):
79 - 88.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. C. Berger and R. G. Hawley
Interferon-beta Interrupts Interleukin-6-Dependent Signaling Events in Myeloma Cells
Blood,
January 1, 1997;
89(1):
261 - 271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Reichner, J. A. Mulligan, M. E. Palla, D. C. Hixson, J. E. Albina, and K. I. Bland
Interleukin-6 Production by Rat Hepatocellular Carcinoma Cells Is Associated With Metastatic Potential but Not With Tumorigenicity
Arch Surg,
April 1, 1996;
131(4):
360 - 365.
[Abstract]
[PDF]
|
|
|
|
|
